As Montefiore Einstein’s Chief of Hematology, Director of the Thrombosis Prevention and Treatment Program, Co-director of the Hemophilia Treatment Center and Co-director of the Woman’s Blood Disorder Clinic, Dr. Henny Billett has seen a lot of changes in the way blood disorders are treated from when she was a T32 research fellow in hematology at Montefiore. And she has also been a part of those changes.
“In the early stage of my career, there was little we could do beyond what was standard at the time for thrombosis, hemophilia and sickle cell disease. Now we have major treatment advances that are life changing when for so long these blood disorders were life limiting,” says Billett.
Ten years ago, Billett’s Thrombosis Program was among the first in the country to manage bridging parenteral anticoagulation as an outpatient therapy for patients with thrombosis, decreasing hospital stays and improving quality of life. Now, with newer, more effective oral anticoagulants that have fewer bleeding complications and require minimal monitoring with little or no need for parenteral therapy, the Thrombosis Program is mostly outpatient, staffed by NPs with expertise and experience. Similarly, for patients with hemophilia, innovative research has led to bispecific antibody therapy, small interfering RNA therapies as well as recombinant clotting factor therapies that can be used preventatively. While not a cure for hemophilia, these offer many patients peace of mind, more freedom and longer lifespans. And because these therapies do not rely on human blood plasma, patients are not at risk of contracting bloodborne infections, such as hepatitis and HIV, which only a few decades ago were responsible for the deaths of over 90% of the New York hemophilia community. In 2015, Billett and Jennifer Davila, MD, her pediatric co-director, received federal designation for their clinic as a Comprehensive Hemophilia Treatment Center, Montefiore’s first. The Hemophilia Treatment Center at Montefiore has more than tripled its patient population in five years.